MMRGlobal, Inc. (fka MMRF)

[EZ2]

"T" ~~ Is there any way we can determine if this "might" be related to anti CD-20 properties ? ie. CT filing today.

==================================================



Parsed from recent 8-K just as refernece:

Shareholder C: "Bob, can you tell me what the Company is doing with its biotech assets. Can MMR make money from
them?"


Lorsch: "Clearly, our plan is to monetize them. We have a powerful Board of Advisors assisting us with this, including Fred
Middleton, Managing Director of Sanderling Ventures, and Ivor Royston, M.D., Founding Managing Member of Forward
Ventures and a co-founder of IDEC Pharmaceuticals (now Biogen Idec). Sanderling and Forward Ventures together
previously were the largest investors in Favrille, Inc., the predecessor public company to MMR, which raised more than $150
million from investors to fund its clinical efforts to develop a cancer vaccine to treat lymphomas. Those two funds alone
invested more than $50 million in Favrille and, therefore, there is a rather significant interest in helping us recover those
funds with these assets. Our anti-CD20 monoclonal antibodies as well as data, tissue samples and other technologies from the
Company's Specifid vaccine trials and manufacturing processes work similar to Provenge from Dendreon, a company that
has emerged from the lab to be a multi-billion dollar drug company based on recent FDA approvals of Provenge. Their drug
targets prostate cancer patients in a similar way to our vaccine trials intended to target lymphoma. It uses the body's own
immune system to target and attack cancer cells. We are spending considerable funds to resurrect patents and related
Intellectual Property around the world and we are actively pursuing relationships to utilize these assets through independent
consultants."